CVRx plans to hold an IPO to raise up to $75 million as it seeks to further commercialize its neuromodulation device to treat the heart. That’s according to a June 4 registration statement with the U.S. Securities and Exchange Commission that follows up on a registration confidentially filed with the SEC in April. The plan […]
Initial Public Offering (IPO)
Memic may go public through merger with SPAC
Memic Innovative Surgery is reportedly eyeing a move to go public through a merger with SPAC MedTech Acquisition Corp. Bloomberg reported that people with knowledge of the matter say that Memic, which develops Hominis, the first FDA-approved, robotically assisted surgical device for performing transvaginal hysterectomy, is in talks over going public with the SPAC. A […]
Gyroscope Therapeutics launches IPO roadshow
Gyroscope Therapeutics announced today that it launched the roadshow for its initial public offering of nearly 7 million shares. London-based Gyroscope’s U.S. offering includes up to 6.75 million American Depository Shares (ADSs) representing 6.75 million ordinary shares, according to a news release. Get the full story at our sister site, Drug Delivery Business News.
MedTech 100 roundup: New heights reached again
One week after recording its all-time best performance, the medtech industry again topped itself, storming even further ahead. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — has been on the rise since April began, with last week’s mark of 112.25 (April 16) representing an all-time best, topping the […]
NeuroPace shares take off on first day of trading
Epilepsy treatment developer NeuroPace (NSDQ:NPCE) shares skyrocketed today during its first day of trading on the Nasdaq market. Mountain View, Calif.-based NeuroPace shares were trading up 37.4% at $23.35 per share in mid-afternoon trading today. The company announced last month that it filed with the SEC to raise up to $75 million in an initial […]
MedTech 100 roundup: Industry skies to all-time high
The medtech industry hit a slight lull in the early stages of 2021 and, after signs of a rebound, it has soared beyond levels ever before seen. MassDevice‘s MedTech 100 Index had been building up steam in the month of April, rising from 102.16 points at the beginning of March all the way to 109.39 to […]
MedTech 100 roundup: Industry roars back
In the blink of an eye, the medtech industry exited its spring slump and neared its all-time best performance levels. MassDevice‘s MedTech 100 Index offered signs of a rebound last week and has built on that momentum, registering a final tally of 109.39 points on April 9. That represents a 2.9% increase from the 106.26-point mark […]
MedTech 100 roundup: Heading back to previous heights?
Although March brought on tough times for top stocks in the medtech industry, April is already showing signs of a rebound. The year’s strong start, during which MassDevice‘s MedTech 100 index notched an all-time best of 110.96 points (Feb. 15) came to an end later that month and carried over into March, with the index hitting its lowest […]
NeuroPace files for $75M IPO
Refractory focal epilepsy treatment developer NeuroPace last week filed with the SEC to raise up to $75 million in an initial public offering. Mountain View, Calif-based NeuroPace develops the RNS system, which it touts as the world’s only closed-loop brain-responsive neurostimulation system designed to prevent seizures at their source. The RNS system includes a neurostimulator, […]
Former Verb Surgical CEO has a medtech SPAC, planning a $175M IPO
A group of medical device industry insiders — including former Verb Surgical and Volcano Corp. CEO Scott Huennekens — is planning a $175 million IPO for a special purpose acquisition company (SPAC). Los Angeles–based VIDA FLaSH Acquisitions filed a form S-1 with the U.S. Securities and Exchange Commission on Feb. 18 for a proposed IPO […]
PavMed to spin off subsidiary Lucid Diagnostics
Pavmed (NSDQ:PAVM) announced today that its majority-owned subsidiary Lucid Diagnostics will spin off into a separate public company. In a news release, Pavmed said Lucid Diagnostics intends to spin off if favorable market conditions continue to hold, whether it be through an initial public offering (IPO) or a business combination with a healthcare special purpose acquisition corporation. […]